T1	CHEM 1 12	Teduglutida
#1	AnnotatorNotes T1	C1530889; teduglutide; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T2	DISO 39 66	síndrome de intestino corto
#2	AnnotatorNotes T2	C0036992; Short Bowel Syndrome; Disease or Syndrome
T3	DISO 266 269	SIC
#3	AnnotatorNotes T3	C0036992; Short Bowel Syndrome; Disease or Syndrome
T4	PROC 85 105	nutrición parenteral
#4	AnnotatorNotes T4	C0030547; Parenteral Nutrition; Therapeutic or Preventive Procedure | C0204706; Parenteral alimentation procedure; Therapeutic or Preventive Procedure | C1527385; Parenteral Feeding; Therapeutic or Preventive Procedure
T5	PROC 107 109	NP
#5	AnnotatorNotes T5	C0030547; Parenteral Nutrition; Therapeutic or Preventive Procedure | C0204706; Parenteral alimentation procedure; Therapeutic or Preventive Procedure | C1527385; Parenteral Feeding; Therapeutic or Preventive Procedure
T6	DISO 143 157	complicaciones
#6	AnnotatorNotes T6	C0009566; Complication; Pathologic Function
T7	DISO 237 264	síndrome de intestino corto
#7	AnnotatorNotes T7	C0036992; Short Bowel Syndrome; Disease or Syndrome
T8	DISO 427 430	SIC
#8	AnnotatorNotes T8	C0036992; Short Bowel Syndrome; Disease or Syndrome
T9	CHEM 275 286	teduglutida
#9	AnnotatorNotes T9	C1530889; teduglutide; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T10	CHEM 291 312	análogo del péptido-2
#10	AnnotatorNotes T10	C3864918; GLP-2 Analog; Pharmacologic Substance
T11	CHEM 324 332	glucagón
#11	AnnotatorNotes T11	C0017687; glucagon; Amino Acid, Peptide, or Protein · Pharmacologic Substance · Hormone
T12	Observation 733 751	dependientes de NP
T13	CHEM 524 535	teduglutida
#13	AnnotatorNotes T13	C1530889; teduglutide; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T14	CHEM 570 581	teduglutida
#14	AnnotatorNotes T14	C1530889; teduglutide; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T15	PROC 614 684	estudio en fase III de 24 semanas, doble ciego, controlado con placebo
T16	DISO 708 724	fallo intestinal
#15	AnnotatorNotes T16	C5544517; Intestinal Failure; Disease or Syndrome
T17	ANAT 714 724	intestinal
#16	AnnotatorNotes T17	C0021853; Intestines; Body Part, Organ, or Organ Component | C1318303; Entire intestine; Body Part, Organ, or Organ Component
T18	PROC 749 751	NP
#17	AnnotatorNotes T18	C0030547; Parenteral Nutrition; Therapeutic or Preventive Procedure | C0204706; Parenteral alimentation procedure; Therapeutic or Preventive Procedure | C1527385; Parenteral Feeding; Therapeutic or Preventive Procedure
T19	CHEM 813 824	teduglutida
#18	AnnotatorNotes T19	C1530889; teduglutide; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T20	PROC 836 843	placebo
#19	AnnotatorNotes T20	C0032042; Placebos; Therapeutic or Preventive Procedure
T21	CHEM 940 951	teduglutida
#20	AnnotatorNotes T21	C1530889; teduglutide; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T22	PROC 965 972	placebo
#21	AnnotatorNotes T22	C0032042; Placebos; Therapeutic or Preventive Procedure
T23	PROC 1041 1043	NP
#22	AnnotatorNotes T23	C0030547; Parenteral Nutrition; Therapeutic or Preventive Procedure | C0204706; Parenteral alimentation procedure; Therapeutic or Preventive Procedure | C1527385; Parenteral Feeding; Therapeutic or Preventive Procedure
T24	CHEM 1118 1129	teduglutida
#23	AnnotatorNotes T24	C1530889; teduglutide; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T25	PROC 1181 1183	NP
#24	AnnotatorNotes T25	C0030547; Parenteral Nutrition; Therapeutic or Preventive Procedure | C0204706; Parenteral alimentation procedure; Therapeutic or Preventive Procedure | C1527385; Parenteral Feeding; Therapeutic or Preventive Procedure
T26	PROC 1241 1249	tratados
#25	AnnotatorNotes T26	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T27	CHEM 1254 1265	teduglutida
#26	AnnotatorNotes T27	C1530889; teduglutide; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T28	PROC 1278 1285	placebo
#27	AnnotatorNotes T28	C0032042; Placebos; Therapeutic or Preventive Procedure
T29	CHEM 1325 1336	teduglutida
#28	AnnotatorNotes T29	C1530889; teduglutide; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T30	PROC 1344 1363	ensayos en fase III
#29	AnnotatorNotes T30	C0282461; Phase 3 Clinical Trials; Research Activity
T31	PROC 1421 1423	NP
#30	AnnotatorNotes T31	C0030547; Parenteral Nutrition; Therapeutic or Preventive Procedure | C0204706; Parenteral alimentation procedure; Therapeutic or Preventive Procedure | C1527385; Parenteral Feeding; Therapeutic or Preventive Procedure
T32	CHEM 1473 1484	teduglutida
#31	AnnotatorNotes T32	C1530889; teduglutide; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T33	CHEM 1537 1548	teduglutida
#32	AnnotatorNotes T33	C1530889; teduglutide; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T34	PROC 1631 1633	NP
#33	AnnotatorNotes T34	C0030547; Parenteral Nutrition; Therapeutic or Preventive Procedure | C0204706; Parenteral alimentation procedure; Therapeutic or Preventive Procedure | C1527385; Parenteral Feeding; Therapeutic or Preventive Procedure
T35	ANAT 51 60	intestino
#34	AnnotatorNotes T35	C0021853; Intestines; Body Part, Organ, or Organ Component | C1318303; Entire intestine; Body Part, Organ, or Organ Component
T36	ANAT 249 258	intestino
#35	AnnotatorNotes T36	C0021853; Intestines; Body Part, Organ, or Organ Component | C1318303; Entire intestine; Body Part, Organ, or Organ Component
T37	DISO 411 422	sintomático
#36	AnnotatorNotes T37	C1457887; Symptoms; Sign or Symptom
T38	DISO 729 732	SIC
#37	AnnotatorNotes T38	C0036992; Short Bowel Syndrome; Disease or Syndrome
T39	PROC 1444 1469	administración subcutánea
T40	ANAT 1571 1581	intestinal
#38	AnnotatorNotes T40	C0021853; Intestines; Body Part, Organ, or Organ Component | C1318303; Entire intestine; Body Part, Organ, or Organ Component
T41	Observation 1613 1633	dependencia de la NP
#39	AnnotatorNotes T41	C2750746; Dependent on total parenteral nutrition (TPN); Finding (?)
T42	Route 95 105	parenteral
#40	AnnotatorNotes T42	C1518896; Parenteral Route of Drug Administration; Functional Concept
T43	Date 111 124	a largo plazo
T44	Spec_cue 125 130	puede
T45	LIVB 223 232	pacientes
#41	AnnotatorNotes T45	C0030705; Patients; Patient or Disabled Group
T47	Neg_cue 408 410	no
T48	Duration 637 647	24 semanas
T49	LIVB 694 703	Pacientes
#42	AnnotatorNotes T49	C0030705; Patients; Patient or Disabled Group
T50	Frequency 752 768	≥ 3 veces/semana
T51	Duration 777 787	≥ 12 meses
T52	Dose 799 809	0,05 mg/kg
T53	Frequency 853 862	1 vez/día
T54	Date 867 879	la semana 24
T55	Date 1069 1081	la semana 24
T58	Duration 1194 1201	≥ 1 día
T59	Date 1205 1217	la semana 24
T60	LIVB 1231 1240	pacientes
#43	AnnotatorNotes T60	C0030705; Patients; Patient or Disabled Group
T61	LIVB 1300 1309	pacientes
#44	AnnotatorNotes T61	C0030705; Patients; Patient or Disabled Group
T62	Route 1459 1469	subcutánea
#45	AnnotatorNotes T62	C1522438; Subcutaneous Route of Drug Administration; Functional Concept
T64	PHYS 1561 1581	absorción intestinal
#46	AnnotatorNotes T64	C0021826; Intestinal Absorption; Organ or Tissue Function
T65	LIVB 1684 1693	pacientes
#47	AnnotatorNotes T65	C0030705; Patients; Patient or Disabled Group
T66	PHYS 85 94	nutrición
#48	AnnotatorNotes T66	C1442959; Nutrition function; Organism Function
A1	Assertion T6 Speculated
A2	Assertion T37 Negated
R1	Negation Arg1:T47 Arg2:T37	
R2	Location_of Arg1:T35 Arg2:T2	
R4	Has_Route_or_Mode Arg1:T4 Arg2:T42	
R5	Has_Route_or_Mode Arg1:T5 Arg2:T42	
R6	Overlap Arg1:T5 Arg2:T43	
R7	Overlap Arg1:T4 Arg2:T43	
R8	Speculation Arg1:T44 Arg2:T6	
T46	Quantifier_or_Qualifier 158 164	graves
#49	AnnotatorNotes T46	C1547227; Severe - Severity of Illness Code; Intellectual Product
R9	Has_Quantifier_or_Qualifier Arg1:T6 Arg2:T46	
A3	Assertion T46 Speculated
T56	Quantifier_or_Qualifier 183 193	importante
#50	AnnotatorNotes T56	C3898777; Important; Qualitative Concept
T57	Observation 173 182;194 215	deterioro de la calidad de vida
#51	AnnotatorNotes T57	C4049260; Impaired quality of life; Finding
R10	Experiences Arg1:T45 Arg2:T57	
R11	Has_Quantifier_or_Qualifier Arg1:T57 Arg2:T56	
R12	Experiences Arg1:T45 Arg2:T7	
R13	Location_of Arg1:T36 Arg2:T7	
R14	Location_of Arg1:T36 Arg2:T3	
R15	Causes Arg1:T6 Arg2:T57	
R16	Before Arg1:T4 Arg2:T6	
R17	Before Arg1:T5 Arg2:T6	
R18	Experiences Arg1:T45 Arg2:T6	
R19	Experiences Arg1:T45 Arg2:T5	
R20	Experiences Arg1:T45 Arg2:T4	
R21	Experiences Arg1:T45 Arg2:T66	
T63	CONC 456 461;476 484	datos clínicos
#52	AnnotatorNotes T63	C1516606; Clinical Data; Intellectual Product
T67	CONC 456 473	datos preclínicos
R22	Has_Duration_or_Interval Arg1:T15 Arg2:T48	
R23	Location_of Arg1:T17 Arg2:T16	
R24	Experiences Arg1:T49 Arg2:T16	
R25	Causes Arg1:T38 Arg2:T16	
R26	Experiences Arg1:T49 Arg2:T38	
R27	Experiences Arg1:T49 Arg2:T12	
R28	Overlap Arg1:T16 Arg2:T12	
R29	Experiences Arg1:T49 Arg2:T18	
R31	Has_Frequency Arg1:T18 Arg2:T50	
R32	Has_Duration_or_Interval Arg1:T18 Arg2:T51	
R33	Experiences Arg1:T49 Arg2:T19	
R34	Experiences Arg1:T49 Arg2:T20	
R35	Has_Dose_or_Strength Arg1:T19 Arg2:T52	
R36	Has_Frequency Arg1:T20 Arg2:T53	
R37	Has_Frequency Arg1:T19 Arg2:T53	
T68	Observation 908 921	respondedores
#53	AnnotatorNotes T68	C0919876; Therapy responder; Finding
R38	Overlap Arg1:T68 Arg2:T54	
R39	Overlap Arg1:T68 Arg2:T21	
R40	Overlap Arg1:T68 Arg2:T22	
T70	CONC 1054 1065	valor basal
#55	AnnotatorNotes T70	C1442488; Baseline; Quantitative Concept
R42	Overlap Arg1:T23 Arg2:T70	
R43	Overlap Arg1:T23 Arg2:T55	
R44	Has_Duration_or_Interval Arg1:T25 Arg2:T58	
R45	Overlap Arg1:T25 Arg2:T59	
R46	Experiences Arg1:T60 Arg2:T25	
R47	Experiences Arg1:T60 Arg2:T26	
R48	Used_for Arg1:T27 Arg2:T26	
R49	Experiences Arg1:T60 Arg2:T28	
R52	Experiences Arg1:T61 Arg2:T29	
T72	Observation 1396 1423	autonomía completa de la NP
R53	Experiences Arg1:T61 Arg2:T72	
R54	Causes Arg1:T29 Arg2:T72	
R55	Used_for Arg1:T32 Arg2:T39	
R56	Has_Route_or_Mode Arg1:T32 Arg2:T62	
T73	Observation 1485 1499	se toleró bien
R57	Overlap Arg1:T39 Arg2:T73	
R58	Location_of Arg1:T40 Arg2:T64	
T75	Observation 1625 1633;1659 1672	de la NP independencia
R60	Experiences Arg1:T65 Arg2:T33	
R61	Causes Arg1:T33 Arg2:T75	
R62	Experiences Arg1:T65 Arg2:T64	
R63	Experiences Arg1:T65 Arg2:T41	
R64	Experiences Arg1:T65 Arg2:T75	
R65	Experiences Arg1:T65 Arg2:T34	
R66	Causes Arg1:T33 Arg2:T64	
R67	Experiences Arg1:T61 Arg2:T31	
#58	AnnotatorNotes T73	C5684674; patient tolerated procedure well; Finding
R3	Overlap Arg1:T6 Arg2:T7	
R41	Overlap Arg1:T6 Arg2:T3	
R50	Causes Arg1:T8 Arg2:T37	
#12	AnnotatorNotes T12	C2750746; Dependent on total parenteral nutrition (TPN); Finding (?)
R30	Overlap Arg1:T38 Arg2:T12	
#54	AnnotatorNotes T43	C0443252; Long-term; Temporal Concept
#56	AnnotatorNotes T39	C0812152; Medication administration: subcutaneous; Therapeutic or Preventive Procedure
A4	Experiencer T65 Patient
A5	Experiencer T61 Patient
A6	Experiencer T45 Patient
A7	Experiencer T49 Patient
A8	Experiencer T60 Patient
